靶向慢性髓性白血病干细胞的缺氧诱导因子抑制剂吖啶黄
慢性髓性白血病(CML)由造血干细胞驱动并表达持续激活的BCR/Abl酪氨酸激酶,酪氨酸激酶抑制剂(TKI)可诱导缓解但不靶向白血病干细胞(LSC)。本研究显示缺氧诱导因子-1(HIF-1)抑制剂吖啶黄(ACF)可降低CML细胞存活与生长、下调c-Myc及干性相关基因,在体外干细胞实验中靶向CML细胞(含12例CML患者原代细胞)的干细胞潜能而TKI不能,并在小鼠CML模型中减少白血病发生与LSC维持,且对非CML造血细胞影响较轻。作者据此提出ACF作为预防CML复发及与TKI联合增强缓解诱导的新治疗途径。
要点
- HIF-1抑制剂吖啶黄(ACF)降低CML细胞存活与生长,并下调c-Myc及干性相关基因表达。
- 体外干细胞实验中ACF(而非TKI)靶向CML细胞干细胞潜能,包括12例CML患者原代细胞。
- 小鼠CML模型中ACF减少白血病发生并降低LSC维持,对非CML造血细胞影响较轻。
核心结论
- 作者提出吖啶黄(ACF)作为预防CML复发、并与TKI联合增强缓解诱导的新治疗途径。
- ACF是美国食品药品监督管理局(FDA)批准用于人类非肿瘤适应症的药物。
研究设计与样本
- 研究采用体外干细胞实验、12例CML患者原代细胞及小鼠CML模型评估ACF对CML干细胞潜能的影响。
- 研究比较ACF与TKI对CML细胞干细胞潜能的作用,并评估ACF对非CML造血细胞的体外和体内影响。
主要发现
- ACF降低CML细胞存活与生长,并伴随c-Myc及干性相关基因表达下降。
- 体外干细胞实验中ACF(而非TKI)靶向CML细胞的干细胞潜能,包括来自12例CML患者的原代细胞。
- 小鼠CML模型中ACF减少白血病发生并降低LSC维持。
- ACF在体外和体内对非CML造血细胞的影响显著较轻。
临床怎么用
- 作者提出ACF作为预防CML复发并与TKI联合增强缓解诱导的新治疗途径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myeloid leukemia (CML) is a hematopoietic stem cell (HSC)-driven neoplasia characterized by expression of the constitutively active tyrosine kinase BCR/Abl. CML therapy based on tyrosine kinase inhibitors (TKIs) is highly effective in inducing remission but not in targeting leukemia stem cells (LSCs), which sustain minimal residual disease and are responsible for CML relapse following discontinuation of treatment. The identification of molecules capable of targeting LSCs appears therefore of primary importance to aim at CML eradication. LSCs home in bone marrow areas at low oxygen tension, where HSCs are physiologically hosted. This study addresses the effects of pharmacological inhibition of hypoxia-inducible factor-1 (HIF-1), a critical regulator of LSC survival, on the maintenance of CML stem cell potential. We found that the HIF-1 inhibitor acriflavine (ACF) decreased survival and growth of CML cells. These effects were paralleled by decreased expression of c-Myc and stemness-related genes. Using different in vitro stem cell assays, we showed that ACF, but not TKIs, targets the stem cell potential of CML cells, including primary cells explanted from 12 CML patients. Moreover, in a murine CML model, ACF decreased leukemia development and reduced LSC maintenance. Importantly, ACF exhibited significantly less-severe effects on non-CML hematopoietic cells in vitro and in vivo. Thus, we propose ACF, a US Food and Drug Administration (FDA)-approved drug for nononcological use in humans, as a novel therapeutic approach to prevent CML relapse and, in combination with TKIs, enhance induction of remission.
引用
- Cheloni G, Tanturli M, Tusa I, et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017. PMID: 28576876. doi:10.1182/blood-2016-10-745588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。